About LanC-like protein 2
LanC-like protein 2 (LANCL2) is a protein
from Homo sapiens identified by UniProt accession
Q9NS86, 450 residues long.
MolForge cross-references it against 0 known binders and
87 disease associations.
Target properties
| Protein name | LanC-like protein 2 |
| UniProt accession | Q9NS86 |
| Gene | LANCL2 |
| Organism | Homo sapiens |
| Length | 450 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (87)
Diseases linked to this target (Open Targets).
- respiratory tract infectious disorder · score 0.30
- glioblastoma · score 0.08
- lung adenocarcinoma · score 0.07
- glioblastoma multiforme · score 0.07
- neoplasm · score 0.07
- X-linked severe congenital neutropenia · score 0.06
- Immunodeficiency due to interleukin-1 receptor-associated kinase-4 deficiency · score 0.05
- common variable immunodeficiency · score 0.05
- isolated agammaglobulinemia · score 0.05
- combined immunodeficiency with skin granulomas · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9NS86-F1 | alphafold | PREDICTED | 91.99 | — |
Amino-acid sequence (450 residues)
MGETMSKRLK LHLGGEAEME ERAFVNPFPD YEAAAGALLA SGAAEETGCV RPPATTDEPG LPFHQDGKII HNFIRRIQTK IKDLLQQMEE GLKTADPHDC SAYTGWTGIA LLYLQLYRVT CDQTYLLRSL DYVKRTLRNL NGRRVTFLCG DAGPLAVGAV IYHKLRSDCE SQECVTKLLQ LQRSVVCQES DLPDELLYGR AGYLYALLYL NTEIGPGTVC ESAIKEVVNA IIESGKTLSR EERKTERCPL LYQWHRKQYV GAAHGMAGIY YMLMQPAAKV DQETLTEMVK PSIDYVRHKK FRSGNYPSSL SNETDRLVHW CHGAPGVIHM LMQAYKVFKE EKYLKEAMEC SDVIWQRGLL RKGYGICHGT AGNGYSFLSL YRLTQDKKYL YRACKFAEWC LDYGAHGCRI PDRPYSLFEG MAGAIHFLSD VLGPETSRFP AFELDSSKRD
Explore LanC-like protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets